Microbix Biosystems Inc. (MBXBF)
USD 0.27
(10.2%)
USD 0.27
(10.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.96 Million CAD | 35.27% |
| 2022 | -7.66 Million CAD | -240.46% |
| 2021 | -2.25 Million CAD | -137.02% |
| 2020 | 6.08 Million CAD | -11.77% |
| 2019 | 6.89 Million CAD | 10.93% |
| 2018 | 6.21 Million CAD | -13.94% |
| 2017 | 7.22 Million CAD | -1.99% |
| 2016 | 7.36 Million CAD | 3.95% |
| 2015 | 7.08 Million CAD | 31.97% |
| 2014 | 5.37 Million CAD | 8.11% |
| 2013 | 4.96 Million CAD | -25.72% |
| 2012 | 6.68 Million CAD | 13.98% |
| 2011 | 5.86 Million CAD | -1.94% |
| 2010 | 5.98 Million CAD | 19.93% |
| 2009 | 4.98 Million CAD | 902.39% |
| 2008 | 497.8 Thousand CAD | -61.91% |
| 2007 | 1.3 Million CAD | 47.43% |
| 2006 | 886.45 Thousand CAD | 244.19% |
| 2005 | -614.76 Thousand CAD | 5.46% |
| 2004 | -650.29 Thousand CAD | -547.6% |
| 2003 | -100.41 Thousand CAD | 52.74% |
| 2002 | -212.46 Thousand CAD | -52.45% |
| 2001 | -139.36 Thousand CAD | -170.36% |
| 2000 | 198.08 Thousand CAD | -60.38% |
| 1999 | 500 Thousand CAD | 155.56% |
| 1998 | -900 Thousand CAD | 83.93% |
| 1997 | -5.6 Million CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -6.45 Million CAD | -4.78% |
| 2024 Q2 | -6.15 Million CAD | -0.87% |
| 2024 Q1 | -6.1 Million CAD | -23.06% |
| 2023 FY | -4.96 Million CAD | 35.27% |
| 2023 Q2 | -5.17 Million CAD | 19.81% |
| 2023 Q3 | -6.84 Million CAD | -32.16% |
| 2023 Q1 | -6.45 Million CAD | 15.74% |
| 2023 Q4 | -4.96 Million CAD | 27.52% |
| 2022 FY | -7.66 Million CAD | -240.46% |
| 2022 Q2 | -5.84 Million CAD | -34.66% |
| 2022 Q3 | -8.32 Million CAD | -42.35% |
| 2022 Q1 | -4.34 Million CAD | -92.89% |
| 2022 Q4 | -7.66 Million CAD | 7.92% |
| 2021 Q1 | 5.72 Million CAD | -5.86% |
| 2021 Q2 | 4.78 Million CAD | -16.4% |
| 2021 Q3 | -1.17 Million CAD | -124.46% |
| 2021 FY | -2.25 Million CAD | -137.02% |
| 2021 Q4 | -2.25 Million CAD | -92.26% |
| 2020 Q1 | 7.26 Million CAD | 5.45% |
| 2020 FY | 6.08 Million CAD | -11.77% |
| 2020 Q3 | 5.73 Million CAD | -5.48% |
| 2020 Q4 | 6.08 Million CAD | 6.09% |
| 2020 Q2 | 6.06 Million CAD | -16.57% |
| 2019 FY | 6.89 Million CAD | 10.93% |
| 2019 Q1 | 6.26 Million CAD | 0.84% |
| 2019 Q2 | 6.74 Million CAD | 7.69% |
| 2019 Q3 | 7.11 Million CAD | 5.37% |
| 2019 Q4 | 6.89 Million CAD | -3.06% |
| 2018 FY | 6.21 Million CAD | -13.94% |
| 2018 Q2 | 6.1 Million CAD | -2.46% |
| 2018 Q3 | 6.38 Million CAD | 4.55% |
| 2018 Q4 | 6.21 Million CAD | -2.65% |
| 2018 Q1 | 6.25 Million CAD | -13.32% |
| 2017 Q4 | 7.22 Million CAD | 7.38% |
| 2017 Q2 | 6.95 Million CAD | 3.3% |
| 2017 FY | 7.22 Million CAD | -1.99% |
| 2017 Q1 | 6.72 Million CAD | -8.68% |
| 2017 Q3 | 6.72 Million CAD | -3.25% |
| 2016 Q2 | 7.42 Million CAD | 2.15% |
| 2016 Q4 | 7.36 Million CAD | -0.87% |
| 2016 Q1 | 7.27 Million CAD | 2.58% |
| 2016 Q3 | 7.43 Million CAD | 0.08% |
| 2016 FY | 7.36 Million CAD | 3.95% |
| 2015 FY | 7.08 Million CAD | 31.97% |
| 2015 Q1 | 5.72 Million CAD | 6.54% |
| 2015 Q4 | 7.08 Million CAD | 6.82% |
| 2015 Q2 | 5.41 Million CAD | -5.41% |
| 2015 Q3 | 6.63 Million CAD | 22.59% |
| 2014 Q4 | 5.37 Million CAD | -7.18% |
| 2014 Q1 | 5.15 Million CAD | 3.79% |
| 2014 FY | 5.37 Million CAD | 8.11% |
| 2014 Q3 | 5.78 Million CAD | 14.65% |
| 2014 Q2 | 5.04 Million CAD | -2.12% |
| 2013 Q2 | 6.91 Million CAD | 3.1% |
| 2013 Q4 | 4.96 Million CAD | -28.49% |
| 2013 Q3 | 6.94 Million CAD | 0.53% |
| 2013 Q1 | 6.7 Million CAD | 0.21% |
| 2013 FY | 4.96 Million CAD | -25.72% |
| 2012 FY | 6.68 Million CAD | 13.98% |
| 2012 Q4 | 6.68 Million CAD | 22.48% |
| 2012 Q3 | 5.46 Million CAD | -2.8% |
| 2012 Q2 | 5.61 Million CAD | -4.78% |
| 2012 Q1 | 5.9 Million CAD | 0.55% |
| 2011 Q2 | 6.14 Million CAD | 10.28% |
| 2011 FY | 5.86 Million CAD | -1.94% |
| 2011 Q4 | 5.86 Million CAD | -4.1% |
| 2011 Q3 | 6.11 Million CAD | -0.37% |
| 2011 Q1 | 5.56 Million CAD | -6.93% |
| 2010 Q3 | 5.62 Million CAD | 14.03% |
| 2010 Q2 | 4.92 Million CAD | -11.24% |
| 2010 Q1 | 5.55 Million CAD | 11.3% |
| 2010 Q4 | 5.98 Million CAD | 6.46% |
| 2010 FY | 5.98 Million CAD | 19.93% |
| 2009 FY | 4.98 Million CAD | 902.39% |
| 2009 Q3 | 4.71 Million CAD | 7.99% |
| 2009 Q4 | 4.98 Million CAD | 5.91% |
| 2009 Q1 | 2.88 Million CAD | 479.02% |
| 2009 Q2 | 4.36 Million CAD | 51.36% |
| 2008 Q2 | -2.54 Million CAD | 40.98% |
| 2008 Q1 | -4.3 Million CAD | -429.68% |
| 2008 FY | 497.8 Thousand CAD | -61.91% |
| 2008 Q4 | 497.8 Thousand CAD | 1235.2% |
| 2008 Q3 | 37.28 Thousand CAD | 101.47% |
| 2007 Q4 | 1.3 Million CAD | -2.63% |
| 2007 FY | 1.3 Million CAD | 47.43% |
| 2007 Q1 | 1.51 Million CAD | 70.91% |
| 2007 Q2 | 1.79 Million CAD | 18.44% |
| 2007 Q3 | 1.34 Million CAD | -25.2% |
| 2006 Q4 | 886.45 Thousand CAD | 629.91% |
| 2006 FY | 886.45 Thousand CAD | 244.19% |
| 2006 Q2 | -374.3 Thousand CAD | 18.99% |
| 2006 Q1 | -462.04 Thousand CAD | 24.84% |
| 2006 Q3 | 121.44 Thousand CAD | 132.45% |
| 2005 Q1 | -760.41 Thousand CAD | -16.93% |
| 2005 Q2 | -1 Million CAD | -31.76% |
| 2005 FY | -614.76 Thousand CAD | 5.46% |
| 2005 Q4 | -614.76 Thousand CAD | 33.53% |
| 2005 Q3 | -924.81 Thousand CAD | 7.7% |
| 2004 Q3 | -148.71 Thousand CAD | -13365.83% |
| 2004 Q2 | 1121.00 CAD | 101.06% |
| 2004 Q4 | -650.29 Thousand CAD | -337.29% |
| 2004 FY | -650.29 Thousand CAD | -547.6% |
| 2004 Q1 | -105.5 Thousand CAD | -5.07% |
| 2003 Q4 | -100.41 Thousand CAD | -222.85% |
| 2003 Q2 | 220.65 Thousand CAD | 202.58% |
| 2003 Q1 | -215.09 Thousand CAD | -1.24% |
| 2003 FY | -100.41 Thousand CAD | 52.74% |
| 2003 Q3 | 81.74 Thousand CAD | -62.96% |
| 2002 Q3 | 149.21 Thousand CAD | 482.33% |
| 2002 FY | -212.46 Thousand CAD | -52.45% |
| 2002 Q2 | 25.62 Thousand CAD | 130.46% |
| 2002 Q1 | -84.12 Thousand CAD | 39.64% |
| 2002 Q4 | -212.46 Thousand CAD | -242.39% |
| 2001 Q1 | 202.74 Thousand CAD | 2.35% |
| 2001 FY | -139.36 Thousand CAD | -170.36% |
| 2001 Q3 | 96.3 Thousand CAD | -38.91% |
| 2001 Q4 | -139.36 Thousand CAD | -244.71% |
| 2001 Q2 | 157.64 Thousand CAD | -22.25% |
| 2000 FY | 198.08 Thousand CAD | -60.38% |
| 2000 Q1 | 400 Thousand CAD | -20.0% |
| 2000 Q4 | 198.08 Thousand CAD | -33.97% |
| 2000 Q3 | 300 Thousand CAD | -50.0% |
| 2000 Q2 | 600 Thousand CAD | 50.0% |
| 1999 Q2 | -100 Thousand CAD | 50.0% |
| 1999 Q4 | 500 Thousand CAD | 66.67% |
| 1999 Q3 | 300 Thousand CAD | 400.0% |
| 1999 Q1 | -200 Thousand CAD | 77.78% |
| 1999 FY | 500 Thousand CAD | 155.56% |
| 1998 Q4 | -900 Thousand CAD | 52.63% |
| 1998 FY | -900 Thousand CAD | 83.93% |
| 1998 Q3 | -1.9 Million CAD | 24.0% |
| 1998 Q2 | -2.5 Million CAD | 45.65% |
| 1998 Q1 | -4.6 Million CAD | 17.86% |
| 1997 Q2 | 300 Thousand CAD | 150.0% |
| 1997 Q3 | -5.8 Million CAD | -2033.33% |
| 1997 Q1 | -600 Thousand CAD | 0.0% |
| 1997 FY | -5.6 Million CAD | 0.0% |
| 1997 Q4 | -5.6 Million CAD | 3.45% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | 361.263% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 131.473% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1334.584% |
| SQZ Biotechnologies Company | -36.23 Million USD | 86.31% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 321.26% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 111.593% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 21.308% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 635.077% |
| Marizyme, Inc. | 18.56 Million USD | 126.717% |
| Genus plc | 190.6 Million USD | 102.603% |
| Pharming Group N.V. | 109.8 Million USD | 104.518% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 676.718% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 508.7% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 829.583% |
| ContraFect Corporation | -6.02 Million USD | 17.671% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 529.378% |
| IMV Inc. | 7.67 Million USD | 164.678% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 190.172% |
| ONE Bio Corp. | 9.04 Million USD | 154.88% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 138.322% |
| Mesoblast Limited | 55.85 Million USD | 108.882% |
| MultiCell Technologies, Inc. | 90.04 USD | 5510053.354% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 116.237% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.533% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 897.148% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 592.317% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 220.474% |
| Biomind Labs Inc. | 711.4 Thousand USD | 797.378% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 348.134% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 138.739% |
| Skye Bioscience, Inc. | -5.72 Million USD | 13.287% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1479.212% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 321.893% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 3648.655% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 3784.788% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 187.834% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 25071.873% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -575.928% |
| EV Biologics, Inc. | 1.36 Million USD | 462.666% |
| Q BioMed Inc. | 4.06 Million USD | 222.196% |
| GB Sciences, Inc. | 1.74 Million USD | 383.93% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -2599.394% |
| CSL Limited | 10.52 Billion USD | 100.047% |
| Agentix Corp. | 37.63 Thousand USD | 13283.71% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 108.194% |
| Enzolytics Inc. | 981.65 Thousand USD | 605.387% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 176.905% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -637.074% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 325.304% |
| argenx SE | -2.02 Billion USD | 99.755% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 111.422% |
| HST Global, Inc. | 96.79 Thousand USD | 5225.538% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 89.447% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 2505.797% |
| Halberd Corporation | 144.72 Thousand USD | 3528.087% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 170.162% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 43.878% |
| Zenith Capital Corp. | 10.06 Thousand USD | 49396.125% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 283.162% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 307.925% |
| AVAX Technologies, Inc. | -5.9 Million USD | 15.958% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3115.739% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -26983.535% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 2575.234% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 327.737% |
| Helix BioMedix, Inc. | -2.57 Million USD | -93.039% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 124.468% |
| Kadimastem Ltd | -253.1 Thousand USD | -1860.143% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 210.938% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 2565.125% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -378614.656% |
| LadRx Corporation | -2.03 Million USD | -143.616% |
| Cell Source, Inc. | 9.23 Million USD | 153.739% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -24209.888% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 881.08% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 881.08% |
| Affymax, Inc. | -5.59 Million USD | 11.36% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1124.542% |
| Itoco Inc. | 228.3 Thousand USD | 2273.041% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 3748.208% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 200.084% |
| International Stem Cell Corporation | 2.59 Million USD | 291.551% |
| CytoDyn Inc. | 20.26 Million USD | 124.485% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -766694.745% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -53428.054% |
| Qrons Inc. | 351.42 Thousand USD | 1511.719% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 164.38% |
| SYBLEU INC | 473.71 Thousand USD | 1147.291% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -1887.486% |
| Rebus Holdings, Inc. | 305 Thousand USD | 1726.61% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 211.311% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 8048.924% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 327.482% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 244.472% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 158.005% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 742.133% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -296.893% |
| Neutra Corp. | 52.18 Thousand USD | 9606.509% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -99.324% |
| PureTech Health plc | -167.19 Million USD | 97.033% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -1925.725% |
| IXICO plc | -4.44 Million USD | -11.623% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 137.531% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 109.045% |
| CSL Limited | 10.52 Billion USD | 100.047% |
| Cellectis S.A. | -43.81 Million USD | 88.678% |